Net Income (Loss) Attributable to Parent in USD of INTERCEPT PHARMACEUTICALS, INC. from 2010 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
INTERCEPT PHARMACEUTICALS, INC. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2010 to Q3 2023.
  • INTERCEPT PHARMACEUTICALS, INC. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2023 was -$2.79M, a 101% decline year-over-year.
  • INTERCEPT PHARMACEUTICALS, INC. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2023 was -$61.6M, a 130% decline year-over-year.
  • INTERCEPT PHARMACEUTICALS, INC. annual Net Income (Loss) Attributable to Parent for 2022 was $222M.
  • INTERCEPT PHARMACEUTICALS, INC. annual Net Income (Loss) Attributable to Parent for 2021 was -$91.4M, a 66.7% increase from 2020.
  • INTERCEPT PHARMACEUTICALS, INC. annual Net Income (Loss) Attributable to Parent for 2020 was -$275M, a 20.3% increase from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

INTERCEPT PHARMACEUTICALS, INC. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 -$61.6M -$2.79M -$270M -101% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2023
Q2 2023 $209M -$5.86M +$1.67M +22.1% 01 Apr 2023 30 Jun 2023 10-Q 02 Aug 2023
Q1 2023 $207M -$32.1M -$14.9M -85.9% 01 Jan 2023 31 Mar 2023 10-Q 27 Apr 2023
Q4 2022 $222M -$20.8M +$15.5M +42.6% 01 Oct 2022 31 Dec 2022 10-K 02 Mar 2023
Q3 2022 $206M $267M +$271M 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023
Q2 2022 -$64.7M -$7.53M +$3.57M +32.1% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023
Q1 2022 -$68.3M -$17.3M +$23.1M +57.2% 01 Jan 2022 31 Mar 2022 10-Q 27 Apr 2023
Q4 2021 -$91.4M -$36.3M +$15.9M +30.4% 01 Oct 2021 31 Dec 2021 10-K 02 Mar 2023
Q3 2021 -$107M -$3.63M +$62.8M +94.5% 01 Jul 2021 30 Sep 2021 10-K 02 Mar 2023
Q2 2021 -$170M -$11.1M +$52.2M +82.5% 01 Apr 2021 30 Jun 2021 10-K 02 Mar 2023
Q1 2021 -$222M -$40.4M +$52.6M +56.5% 01 Jan 2021 31 Mar 2021 10-K 02 Mar 2023
Q4 2020 -$275M -$52.1M +$46M +46.9% 01 Oct 2020 31 Dec 2020 10-K 25 Feb 2021
Q3 2020 -$321M -$66.5M +$18.4M +21.6% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021
Q2 2020 -$339M -$63.3M +$8.14M +11.4% 01 Apr 2020 30 Jun 2020 10-Q 29 Jul 2021
Q1 2020 -$347M -$93M -$2.71M -3.01% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021
Q4 2019 -$345M -$98.2M -$10.2M -11.5% 01 Oct 2019 31 Dec 2019 10-K 25 Feb 2021
Q3 2019 -$335M -$84.8M -$20.4M -31.6% 01 Jul 2019 30 Sep 2019 10-K 25 Feb 2021
Q2 2019 -$314M -$71.4M +$3.77M +5.02% 01 Apr 2019 30 Jun 2019 10-K 25 Feb 2021
Q1 2019 -$318M -$90.3M -$8.68M -10.6% 01 Jan 2019 31 Mar 2019 10-K 25 Feb 2021
Q4 2018 -$309M -$88M +$23.3M +20.9% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2020
Q3 2018 -$333M -$64.5M +$8.15M +11.2% 01 Jul 2018 30 Sep 2018 10-K 25 Feb 2020
Q2 2018 -$341M -$75.2M +$11.4M +13.1% 01 Apr 2018 30 Jun 2018 10-K 25 Feb 2020
Q1 2018 -$352M -$81.6M +$8.34M +9.27% 01 Jan 2018 31 Mar 2018 10-K 25 Feb 2020
Q4 2017 -$360M -$111M +$8.77M +7.31% 01 Oct 2017 31 Dec 2017 10-K 01 Mar 2019
Q3 2017 -$369M -$72.6M +$16.2M +18.3% 01 Jul 2017 30 Sep 2017 10-K 01 Mar 2019
Q2 2017 -$385M -$86.6M -$9.27M -12% 01 Apr 2017 30 Jun 2017 10-K 01 Mar 2019
Q1 2017 -$376M -$89.9M +$36.7M +29% 01 Jan 2017 31 Mar 2017 10-K 01 Mar 2019
Q4 2016 -$413M -$120M -$31.8M -36% 01 Oct 2016 31 Dec 2016 10-K 28 Feb 2018
Q3 2016 -$381M -$88.8M -$37.9M -74.5% 01 Jul 2016 30 Sep 2016 10-K 28 Feb 2018
Q2 2016 -$343M -$77.3M -$29.4M -61.4% 01 Apr 2016 30 Jun 2016 10-K 28 Feb 2018
Q1 2016 -$314M -$127M -$87.3M -222% 01 Jan 2016 31 Mar 2016 10-K 28 Feb 2018
Q4 2015 -$226M -$88.3M -$53.4M -153% 01 Oct 2015 31 Dec 2015 10-K 01 Mar 2017
Q3 2015 -$173M -$50.9M -$15.1M -42% 01 Jul 2015 30 Sep 2015 10-K 01 Mar 2017
Q2 2015 -$158M -$47.9M -$81.4M -243% 01 Apr 2015 30 Jun 2015 10-K 01 Mar 2017
Q1 2015 -$76.6M -$39.4M +$207M +84% 01 Jan 2015 31 Mar 2015 10-K 01 Mar 2017
Q4 2014 -$283M -$34.8M -$22.5M -182% 01 Oct 2014 31 Dec 2014 10-K 29 Feb 2016
Q3 2014 -$261M -$35.8M -$4.11M -12.9% 01 Jul 2014 30 Sep 2014 10-K 29 Feb 2016
Q2 2014 -$257M $33.5M +$46.9M 01 Apr 2014 30 Jun 2014 10-K 29 Feb 2016
Q1 2014 -$304M -$246M -$236M -2310% 01 Jan 2014 31 Mar 2014 10-K 29 Feb 2016
Q4 2013 -$67.8M -$12.4M +$18.3M +59.7% 01 Oct 2013 31 Dec 2013 10-K 02 Mar 2015
Q3 2013 -$86.1M -$31.7M -$26.6M -512% 01 Jul 2013 30 Sep 2013 10-K 02 Mar 2015
Q2 2013 -$59.6M -$13.5M -$8.39M -165% 01 Apr 2013 30 Jun 2013 10-K 02 Mar 2015
Q1 2013 -$51.2M -$10.2M -$7.53M -281% 01 Jan 2013 31 Mar 2013 10-K 02 Mar 2015
Q4 2012 -$43.6M -$30.7M -$27M -742% 01 Oct 2012 31 Dec 2012 10-K 14 Mar 2014
Q3 2012 -$16.6M -$5.19M -$2.35M -82.6% 01 Jul 2012 30 Sep 2012 10-K 14 Mar 2014
Q2 2012 -$14.3M -$5.09M -$2.17M -74.3% 01 Apr 2012 30 Jun 2012 10-K 14 Mar 2014
Q1 2012 -$12.1M -$2.68M +$653K +19.6% 01 Jan 2012 31 Mar 2012 10-K 14 Mar 2014
Q4 2011 -$12.7M -$3.65M 01 Oct 2011 31 Dec 2011 10-K 01 Apr 2013
Q3 2011 -$2.84M 01 Jul 2011 30 Sep 2011 10-K 01 Apr 2013
Q2 2011 -$2.92M 01 Apr 2011 30 Jun 2011 10-K 01 Apr 2013
Q1 2011 -$3.33M 01 Jan 2011 31 Mar 2011 10-K 01 Apr 2013

INTERCEPT PHARMACEUTICALS, INC. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $222M +$313M 01 Jan 2022 31 Dec 2022 10-K 02 Mar 2023
2021 -$91.4M +$183M +66.7% 01 Jan 2021 31 Dec 2021 10-K 02 Mar 2023
2020 -$275M +$69.8M +20.3% 01 Jan 2020 31 Dec 2020 10-K 02 Mar 2023
2019 -$345M -$35.4M -11.5% 01 Jan 2019 31 Dec 2019 10-K 02 Mar 2022
2018 -$309M +$51.1M +14.2% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021
2017 -$360M +$52.5M +12.7% 01 Jan 2017 31 Dec 2017 10-K 25 Feb 2020
2016 -$413M -$186M -82.3% 01 Jan 2016 31 Dec 2016 10-K 01 Mar 2019
2015 -$226M +$56.8M +20.1% 01 Jan 2015 31 Dec 2015 10-K 28 Feb 2018
2014 -$283M -$215M -318% 01 Jan 2014 31 Dec 2014 10-K 01 Mar 2017
2013 -$67.8M -$24.1M -55.3% 01 Jan 2013 31 Dec 2013 10-K 29 Feb 2016
2012 -$43.6M -$30.9M -243% 01 Jan 2012 31 Dec 2012 10-K 29 Feb 2016
2011 -$12.7M +$2.35M +15.6% 01 Jan 2011 31 Dec 2011 10-K 02 Mar 2015
2010 -$15.1M 01 Jan 2010 31 Dec 2010 10-K 14 Mar 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.